# US 2003/0069244 A1 · Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069244 A1
- Document ID: US20030069244A1
- Status: Published application
- Kind: A1
- Application number: 10/036,293
- Filed: 2001-11-07
- Published: 2003-04-10
- Earliest claimed: 2000-11-17
- Assignees: Bristol-Myers Squibb Company
- Inventors: Katerina Leftheris; John Hynes; Stephen T. Wrobleski; Joel Barrish
- Web page: https://patentgrep.com/patent/US20030069244A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 207/50: Nitrogen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): 1 or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH2, preferably methyl, and X, R1 through R6, and Z are as described in the specification. Advantageously the groups —ZR4R5 taken together comprise an —NH-substituted aryl.

## Claims

### Claim 1

A method of treating one or more conditions associated with p38 kinase activity comprising administering to a patient in need thereof at least one compound having the formula (I):
179
or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:
R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano or NH2;
X is selected from —O—, —OC(═O)—, —S—, —S(═O)—, —SO2—, —C(═O)—, —CO2—, —NR10—, —NR10C(═O)—, —NR10C(═O)NR11—, —NR10CO2—, —NR10SO2—, —NR10SO2NR11—, —SO2NR10—, —C(═O)NR10—, halogen, nitro, and cyano, or X is absent;
Z is selected from O, S, N, and CR20, wherein when Z is CR20, said carbon atom may form an optionally-substituted bicyclic aryl or heteroaryl with R4 and R5;
R1 is hydrogen, —CH3, —OH, —OCH3, —SH, —SCH3, —OC(═O)R21, —S(═O)R22, —SO2R22, —SO2NR24R25, —CO2R21, —C(═O)NR24R25, —NH2, —NR24R25, —NR21SO2NR24R25, —NR21SO2R22, —NR24C(═O)R25, —NR24CO2R25, —NR21C(═O)NR24R25, halogen, nitro, or cyano;
R2 is selected from:
a) hydrogen, provided that R2 is not hydrogen when X is —S(═O)—, —SO2—, —NR10CO2—, or —NR10SO2—;
b) alkyl, alkenyl, and alkynyl optionally substituted with up to four R26 or pentafluoroalkyl;
c) aryl and heteroaryl optionally substituted with up to three R27; and
d) heterocyclo and cycloalkyl optionally substituted with keto (═O), up to three R27, and/or having a carbon-carbon bridge of 3 to 4 carbon atoms; or
e) R2 is absent if X is halogen, nitro or cyano;
(i) R4 is substituted aryl, aryl substituted with NHSO2alkyl, substituted heteroaryl, or an optionally-substituted bicyclic 7-11 membered saturated or unsaturated carbocyclic or heterocyclic ring, and
R5 is hydrogen, alkyl, or substituted alkyl, except when Z is O or S, R5 is absent,
or alternatively,
(ii) R4 and R5 taken together with Z form an optionally-substituted bicyclic 7-11 membered aryl or heteroaryl;
R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, —NR7R8, —OR7, or halogen;
R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclo, and substituted heterocyclo;
R7, R8, R21, R24, and R25 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocylco, and substituted heterocyclo;
R20 is hydrogen, lower alkyl, or substituted alky, or R20 may be absent if the carbon atom to which it is attached together with R4 and R5 is part of an unsaturated bicyclic aryl or heteroaryl;
R22 is alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;
R26 is selected from halogen, trifluoromethyl, haloalkoxy, keto (═O), nitro, cyano, —SR28, —OR28, —NR28R29, —NR28SO2, —NR28SO2R29, —SO2R28, —SO2NR28R29, —CO2R28, —C(═O)R28, —C(═O)NR28R29, —OC(═O)R28, —OC(═O)NR28R29, —NR28C(═O)R29, —NR28CO2R29, ═N—OH, ═N—O-alkyl; aryl optionally substituted with one to three R27; cycloalkyl optionally substituted with keto(═O), one to three R27, or having a carbon-carbon bridge of 3 to 4 carbon atoms; and heterocyclo optionally substituted with keto (═O), one to three R27, or having a carbon-carbon bridge of 3 to 4 carbon atoms; wherein R28 and R29 are each independently selected from hydrogen, alkyl, alkenyl, aryl, aralkyl, C3-7cycloalkyl, and C3-7heterocycle, or may be taken together to form a C3-7heterocycle; and wherein each R28 and R29 in turn is optionally substituted with up to two of alkyl, alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, amino, hydroxy, alkoxy, alkylthio, phenyl, benzyl, phenyloxy, and benzyloxy; and
R27 is selected from alkyl, R32, and C1-4alkyl substituted with one to three R32, wherein each R32 group is independently selected from halogen, haloalkyl, haloalkoxy, nitro, cyano, —SR30, —OR30, —NR30R31, —NR30SO2, —NR30SO2R31, —SO2R30, —SO2NR30R31, —CO2R30, —C(═O)R30, —C(═O)NR30R31, —OC(═O)R30, —OC(═O)NR30R31, —NR30C(═O)R31, —NR30CO2R31, and a 3 to 7 membered carbocyclic or heterocyclic ring optionally substituted with alkyl, halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, nitro, amino, or cyano, wherein R30 and R31 are each independently selected from hydrogen, alkyl, alkenyl, aryl, aralkyl, C3-7cycloalkyl, and heterocycle, or may be taken together to form a C3-7heterocycle.

### Claim 2 (depends on 1)

The method of claim 1 comprising administering to the patient at least one compound having the formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R3 is methyl, —CF3, or —OCH3;
X is selected from —C(═O)—, —CO2—, —NR10—, —NR10C(═O)—, —NR10CO2—, —NR10SO2—, —SO2NR10—, and —C(═O)NR10—, or X is absent;
Z is N;
R2 is hydrogen, C2-6alkyl, C1-4alkyl substituted with up to four R26, pentafluoroalkyl, or aryl or heteroaryl optionally substituted with up to two R27;
R4 is phenyl substituted with one R12 and zero to three R13;
R5 and R10 independently are selected from hydrogen and lower alkyl;
R12 is carbamyl, sulfonamido, arylsulfonylamine, or ureido, each of which is optionally substituted with up to two of hydroxy, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, and aralkyl, or alkylsulfonylamine;
R13 at each occurrence is independently selected from alkyl, substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, —OR14, —C(═O)alkyl, —OC(═O)alkyl, —NR15R16, —SR15, —NO2, —CN, —CO2R15, —CONH2, —SO3H, —S(═O)alkyl, —S(═O)aryl, —NHSO2-aryl-R17, —NHSO2-alkyl, —SO2NHR17, —CONHR17, and —NHC(═O)NHR17;
R14 is hydrogen, alkyl, or aryl;
R15 is hydrogen or alkyl;
R16 is hydrogen, alkyl, aralkyl, or alkanoyl; and
R17 is hydrogen, hydroxy, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, or aralkyl.

### Claim 3

A method of treating one or more conditions associated with p38 kinase activity comprising administering to a patient in need thereof at least one compound having the formula (I):
180
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano or NH2;
X is selected from —O—, —OC(═O)—, —S—, —S(═O)—, —SO2—, —C(═O)—, —CO2—, —NR10—, —NR10C(═O)—, —NR10C(═O)NR11—, —NR10CO2—, —NR10SO2—, —NR10SO2NR11—, —SO2NR10—, —C(═O)NR10—, halogen, nitro, and cyano, or X is absent;
Z is O, S, N, or CR20;
R1 is hydrogen, —CH3, —OH, —OCH3, —SH, —SCH3, —OC(═O)R21, —S(═O)R22, —SO2R22, —SO2NR24R25, —CO2R21, —C(═O)NR24R25, —NH2, —NR21SO2NR24R25, —NR21SO2R22, —NR24C(═O)R25, —NR24CO2R25, —NR21C(═O)NR24R25, halogen, nitro, or cyano;
R2 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, or heterocycloalkyl, or substituted heterocycloalkyl, or when X is halo, nitro or cyano, R2 is absent, provided that R2 is not hydrogen when X is —S(═O)—, —SO2—, —NR10CO2—, or —NR10SO2—;
R4 is substituted aryl, aryl substituted with NHSO2alkyl, substituted heteroaryl, or an optionally-substituted bicyclic 7-11 membered saturated or unsaturated carbocyclic or heterocyclic ring system;
R5 is hydrogen, alkyl, or substituted alkyl, except that when Z is O or S, R5 is absent;
R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, —NR7R8, —OR7, or halogen;
R7, R8, R10, R11, R21, R24, and R25 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo;
R20 is hydrogen, lower alkyl, or substituted alkyl; and
R22 is alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo.

### Claim 4 (depends on 3)

The method of claim 3 comprising administering to the patient at least one compound of formula (I), in which R4 and R5 taken together with Z form:
181
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R12 is attached to any available carbon atom of phenyl ring A and is selected from carbamyl, sulfonamido, arylsulfonylamine, and ureido, each of which is optionally substituted with up to one of hydroxy, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, and aralkyl, or C1-4alkylsulfonylamine;
R13 is attached to any available carbon atom of phenyl ring A and at each occurrence is independently selected from alkyl, substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, —OR14, —C(═O)alkyl, —OC(═O)alkyl, —NR15R16, —SR15, —NO2, —CN, —CO2R15, —CONH2, —SO3H, —S(═O)alkyl, —S(═O)aryl, —NHSO2-aryl-R17, —NHSO2C1-4alkyl, —SO2NHR17, —CONHR17, and —NHC(═O)NHR17;
R14 is hydrogen, alkyl, or aryl;
R15 is hydrogen or alkyl;
R16 is hydrogen, alkyl, aralkyl, or alkanoyl; and
R17 is hydrogen, hydroxy, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, or aralkyl; and
n is 0, 1, 2 or3.

### Claim 5 (depends on 3)

The method of claim 3 comprising administering to the patient at least one compound having the formula (II):
182
or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:
R3 is methyl or CF3;
X is —C(═O)NR10—, —NR10C(═O)—, —C(═O)—, or —CO2—;
R1 is hydrogen, —CH3, —OH, —OCH3, halogen, nitro, or cyano;
Y is —C(═O)NH—, —NHC(═O)NH—, —NHSO2—, or —SO2NH—;
R10 is hydrogen or lower alkyl;
R18 is selected from hydrogen, alkyl, alkoxy, aryl, and aryl substituted with one to three R19, except that when Y is —NHSO2—, R18 is C1-4alkyl, aryl or aryl substituted with R19;
R13 is attached to any available carbon atom of phenyl ring A and at each occurrence is independently selected from alkyl, substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, —OR14, —C(═O)alkyl, —OC(═O)alkyl, —NR15R16, —SR15, —NO2, —CN, —CO2R15, —CONH2, —SO3H, —S(═O)alkyl, —S(═O)aryl, —NHSO2-aryl-R17, —NHSO2C1-4alkyl, —SO2NHR17, —CONHR17, and —NHC(═O)NHR17;
R14, R15, R16 and R17 are hydrogen or alkyl;
R19 at each occurrence is selected from alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, sulfonic acid, alkysulfonyl, sulfonamido, and aryloxy, wherein each group R19 may be further substituted by hydroxy, alkyl, alkoxy, aryl, or aralkyl; and
n is 0, 1 or 2.

### Claim 6 (depends on 3)

The method of claim 3, comprising administering to the patient at least one compound having the formula (Ia), (Ib), or (Ic):
183
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R3 is methyl or CF3;
R2a and R2c, are independently selected from hydrogen, C2-6alkyl, substituted C1-4alkyl, aryl, substituted aryl, benzyl, and substituted benzyl;
R2b is heterocyclo or substituted heterocycle; and
R10 is hydrogen or lower alkyl.

### Claim 7

A compound having the formula (II):
184
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R3 is methyl, CF3, or CH3; R5 is hydrogen or alkyl;
Y is —C(═O)NR23—, —NR23C(═O)NR23—, —SO2NR23, or —NR23SO2—;
R18 and R23 are selected from hydrogen, alkyl, alkoxy, aryl, and aryl substituted with one to three R19, except when Y is —NR23SO2—, R18 is C1-4alkyl or aryl optionally substituted with one to three R19;
X is selected from —O—, —OC(═O)—, —S—, —S(═O)—, —SO2—, —C(═O)—, —CO2—, —NR10—, —NR10C(═O)—, —NR10C(═O)NR 11—, —NR10CO2—, —NR10SO2—, —NR10SO2NR11—, —SO2NR10—, and —C(═O)NR10—, or X is absent;
R1 is hydrogen, —CH3, —OH, —OCH3, —SH, —SCH3, —OC(═O)R21, —S(═O)R22, —SO2R22, —SO2NR24R25, —CO2R21, —C(═O)NR24R25, —NH2, —NR24R25, —NR21SO2NR24R25, —NR21SO2R22, —NR24C(═O)R25, —NR24CO2R25, —NR21C(═O)NR24R25, halogen, nitro, or cyano;
R2 is selected from
a) hydrogen, provided that R2 is not hydrogen when X is —S(═O)—, —SO2—, —NR10CO2—, or —NR10SO2—;
b) alkyl, alkenyl, and alkynyl optionally substituted with up to four R26, or pentafluoroalkyl;
c) aryl and heteroaryl optionally substituted with up to three R27; and
d) heterocyclo and cycloalkyl optionally substituted with keto (═O), up to three R27, and/or having a carbon-carbon bridge of 3 to 4 carbon atoms;
R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, —NR7R8,—OR7, or halogen;
R10 is hydrogen or alkyl;
R13 and R19 at each occurrence are independently selected from alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, C1-4alkylsulfonylamine, sulfonic acid, alkysulfonyl, sulfonamido, and aryloxy, wherein each R13 and/or R19 group may be further substituted by hydroxy, alkyl, substituted alkyl, alkoxy, aryl, or aralkyl;
R7, R8, R21, R24, and R25 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo;
R22 is alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;
R26 is selected from halogen, trifluoromethyl, haloalkoxy, keto (═O), nitro, cyano, —SR28, —OR28, —NR28R29, —NR28SO2, —NR28SO2R29, —SO2R28, —SO2NR28R29, —CO2R28, —C(═O)R28, —C(═O)NR28R29, —OC(═O)R28, —OC(═O)NR28R29, —NR28C(═O)R29, —NR28CO2R29, ═N—OH, ═N—O-alkyl; aryl optionally substituted with one to three R27; cycloalkyl optionally substituted with keto(═O), one to three R27, or having a carbon-carbon bridge of 3 to 4 carbon atoms; and heterocyclo optionally substituted with keto (═O), one to three R27, or having a carbon-carbon bridge of 3 to 4 carbon atoms; wherein R28 and R29 are each independently selected from hydrogen, alkyl, alkenyl, aryl, aralkyl, C3-7cycloalkyl, and C3-7heterocycle, or may be taken together to form a C3-7heterocycle; and wherein each R28 and R29 in turn is optionally substituted with up to two of alkyl, alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, amino, hydroxy, alkoxy, alkylthio, phenyl, benzyl, phenyloxy, and benzyloxy;
R27 is selected from alkyl, R32, and C1-4alkyl substituted with one to three R32, wherein each R32 group is independently selected from halogen, haloalkyl, haloalkoxy, nitro, cyano, —SR30, —OR30, —NR30R31, —NR30SO2, —NR30SO2R31, —SO2R30, —SO2NR30R31, —CO2R30, —C(═O)R30, —C(═O)NR30R31, —OC(═O)R30, —OC(═O)NR30R31, —NR30C(═O)R31, —NR30CO2R31, and a 3 to 7 membered carbocyclic or heterocyclic ring optionally substituted with alkyl, halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, nitro, amino, or cyano, wherein R30 and R31 are each independently selected from hydrogen, alkyl, alkenyl, aryl, aralkyl, C3-7cycloalkyl, and heterocycle, or may be taken together to form a C3-7heterocycle; and
n is 0, 1 or 2.

### Claim 8 (depends on 7)

A compound according to claim 7, having the formula (IIa) or (IIb),
185
or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:
R1 and R10 are hydrogen or —CH3;
R13 is lower alkyl, halogen, trifluoromethoxy, trifluoromethyl, hydroxy, C1-4alkoxy, nitro, or cyano;
R18 is hydroxy; C1-4alkoxy, phenyl, or phenyl substituted with one or two R19;
R23 is hydrogen or lower alkyl; and
n is 0, 1 or 2.

### Claim 9 (depends on 7)

A compound according to claim 7, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein
X is —C(═O)—, —CO2—, —NR10C(═O)—, or —C(═O)NR10—;
Y is —C(═O)NH—, —NHC(═O)NH—, or —NHSO2—;
R5 and R10 are hydrogen or —CH3;
R13 and R19 at each occurrence are independently selected from lower alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, C1-4alkoxy, nitro, and cyano;
R7, R8, R21, R24, and R25 are independently selected from hydrogen and lower alkyl;
R22 is lower alkyl; and
n is 0 or 1.

### Claim 10 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which X-R2 are:
186
R2a is selected from:
a) hydrogen;
b) straight or branched C2-6alkyl;
c) cycloalkyl optionally substituted with keto and/or up to two R27;
d) phenyl optionally substituted with up to two R27; and
e) heterocycle optionally substituted with keto and/or up to two R27;
f) pentafluoroalkyl or C1-4alkyl substituted with up to three of halogen, trifluoromethyl, cyano, OR28, NR28R29, CO2R28, aryl, heterocycle, and/or cycloalkyl, wherein the aryl, heterocycle, and/or cycloalkyl in turn are optionally optionally substituted with up to two of halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, nitro, cyano and alkyl; and
R2b is a monocyclic or bicyclic heterocycle optionally substituted with up to two R27;
R27 at each occurrence is independently selected from hydrogen, alkyl, trifluoromethyl, trifluoromethoxy, halogen, cyano, nitro, amino, hydroxy, alkoxy, phenyl, benzyl, phenyloxy, and benzyloxy; and
R28 and R29 at each occurrence are independently selected from hydrogen, alkyl, alkenyl, phenyl, and benzyl.

### Claim 11 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which:
R2a is selected from:
a) straight or branched C2-6alkyl;
b) phenyl optionally substituted with up to two of halogen, C1-4alkoxy, and trifluoromethyl;
c) C3-6cycloalkyl optionally substituted with up to two C1-4alkyl and/or hydroxy;
d) straight or branched C1-4alkyl substituted with up to three of
i) halogen,
ii) trifluoromethyl,
iii) cyano,
iv) C1-4alkoxy,
v) phenyloxy,
vi) benzyloxy,
vii) NH2, NH(C1-4alkyl), and/or N(C1-4alkyl)2,
viii) phenyl in turn optionally substituted with up to two of halogen and/or methoxy,
ix) heterocycle selected from pyridinyl, indolyl, thiophenyl, furanyl, thiazolyl, thienyl, morpholinyl, tetrahydrofuranyl, triazinyl, piperazinyl, indenyl, and piperadinyl; said heterocycle optionally substituted with one to two C1-4alkyl,
x) C3-6cycloalkyl; and
R2b is a five to seven membered monocyclic heterocycle selected from diazepinyl, morpholinyl, piperidinyl, and pyrrolidinyl, said heterocycle optionally substituted with C1-4alkyl, phenyl, and/or benzyl.

### Claim 12 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which R1 and R10 are independently hydrogen or CH3.

### Claim 13 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which R6 is hydrogen.

### Claim 14 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which Y is —NHC(═O)NH—or —NHSO2—; R18 is aryl or aryl substituted with alkyl, OCH3, CF3, cyano, or halogen.

### Claim 15 (depends on 7)

A compound according to claim 7 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which Y is —C(═O)NR23—, R23 is hydrogen or lower alkyl, and R18 is C1-4alkoxy or aryl optionally substituted with alkyl, OCH3, CF3, cyano or halogen.

### Claim 16 (depends on 7)

A compound according to claim 7, having the formula:
187
in which R33 is lower alkyl.

### Claim 17 (depends on 16)

A compound according to claim 16 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in which R3 and R33 are methyl, R1 and R6 are hydrogen, and R2 is a straight or branched C2-6alkyl or optionally-substituted benzyl.

### Claim 18 (depends on 7)

A compound according to claim 7, which is selected from (i) N-(2,2-Dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
3-[[6-[(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]-5-methylpyrrolo [2,1-f][1,2,4]triazin-4-yl]amino]-N-methoxy-4-methylbenzamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(2,2-Dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(1,1-Dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Methoxy-4-methyl-3-[[5-methyl-6-(4-morpholinylcarbonyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide;
N-Cyclohexyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(4-Fluorophenyl)methyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(2-methoxyphenyl)methyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(4-pyridinylmethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-pyridinyl)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-( 1-piperidinyl)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(1R,2S)-2,3-Dihydro-1H-inden-1-yl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo [2,1-f][1,2,4]triazine-6-carboxamide;
N-[(1S,2R)-2,3-Dihydro-1H-inden-1-yl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Methoxy-4-methyl-3-[[5-methyl-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide;
N-Cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Cyclopentyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[2-(4-Fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(Cyclohexylmethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(tetrahydro-2-furanyl)methyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(2-1H-Indol-3-ylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Butyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo [2,1-f][1,2,4]triazine-6-carboxamide;
N-(Cyclopropylmethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(2-Furanylmethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-thienylmethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylcyclohexyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(2-Fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(2,3-Dihydro-1H-inden-2-yl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-( 1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-(4-Fluorophenyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo [2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyphenyl)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(3-methoxyphenyl)methyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(2,6-Dichlorophenyl)methyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(1S)-1-Cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-Methoxy-4-methyl-3-[[5-methyl-6-(1-pyrrolidinylcarbonyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-pyridinylmethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(phenylmethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(4-methyl-2-thiazolyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(3-Fluorophenyl)methyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[1-(4-Fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
N-[(2,4-Difluorophenyl)methyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; and
N-[(2,6-Difluorophenyl)methyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;
4-[[5-[[(4-Cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 4-[[5-[[(4-Cyano-phenyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 4-[[5-[[[(4-Cyanophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; or is (ii) a pharmaceutically-acceptable salt, hydrate, or prodrug thereof.

### Claim 19 (depends on 7)

A compound according to claim 7 which is selected from N-Ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)pyrrolo [2,1-f][1,2,4]triazine-6-carboxamide; 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; and 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; and a pharmaceutically-acceptable salt thereof.

### Claim 20

A compound having the formula (II):
188
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein
R3 is methyl or CF3;
R5 is hydrogen or lower alkyl;
Y is —C(═O)NR23—, —NR23C(═O)NR23—, —NR23SO2—, or —SO2NH2—;
R18 and R23 are selected from hydrogen, alkyl, alkoxy, aryl, and aryl substituted with one to three R19, except when Y is —NR23SO2—, R18 is C1-4alkyl or aryl optionally substituted with one to three R19;
X is selected from —O—, —OC(═O)—, —S—, —S(═O)—, —SO2—, —C(═O)—, —CO2—, —NR10—, —NR10C(═O)—, —NR10C(═O)NR10—, —NR10CO2—, —NR10SO2—, —NR10SO2NR11—, —SO2NR1—, and —C(═O)NR10—, or X is absent;
R1 is hydrogen, —CH3, —OH, —OCH3, —SH, —SCH3, —OC(═O)R21, —S(═O)R22, —SO2R22, —SO2NR24R25, —CO2R21, —C(═O)NR24R25, —NH2, —NR21SO2NR24R25, —NR21SO2R22, —NR24C(═O)R25, —NR24CO2R25, —NR21C(═O)NR24R25, halogen, nitro, or cyano;
R2 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl, or substituted heterocycloalkyl;
R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, —NR7R8, —OR7, or halogen;
R13 and R19 at each occurrence are independently selected from alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, C1-4alkylsulfonylamine, sulfonic acid, alkysulfonyl, sulfonamido, and aryloxy, wherein each group R13 and R19 may be further substituted by hydroxy, alkyl, alkoxy, aryl, or aralkyl;
R7, R8, R21, R24, and R25 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo;
R22 is alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo; and
n is 0, 1 or2.

### Claim 21 (depends on 20)

A compound according to claim 20, having the formula:
189
or a pharmaceutically acceptable salt, prodrug or solvate thereof; wherein.
R18 is alkoxy, aryl, or aryl substituted with R19;
R1 and R10 are hydrogen or —CH3; and
R13 is lower alkyl, halogen, trifluoromethoxy, trifluoromethyl, hydroxy, C1-4alkoxy, nitro, or cyano.

### Claim 22 (depends on 20)

A compound according to claim 20 having the formula:
190
or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which R2 is a straight or branched C2-6alkyl or optionally-substituted benzyl, and R13a and R13b are selected from hydrogen, C1-4alkyl, hydroxy, halogen, cyano, and trifluoromethyl.

### Claim 23 (depends on 20)

A compound according to claim 20 which is N-Ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; or a pharmaceutically acceptale salt comprising a methanesulfonic salt thereof.

### Claim 24 (depends on 20)

A compound according to claim 20 which is 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(l-methylethyl)pyrrolo [2,1-f][1,2,4]triazine-6-carboxamide; or a pharmaceutically acceptale salt thereof.

### Claim 25 (depends on 20)

A compound according to claim 20 which is 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; or a pharmaceutically acceptale salt thereof.

### Claim 26 (depends on 20)

A compound according to claim 20 which is 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; or a pharmaceutically acceptale salt thereof.

### Claim 27 (depends on 20)

A compound according to claim 20 which is 4-[[5-[(Methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; or a pharmaceutically-acceptable salt thereof.

### Claim 28 (depends on 7)

A pharmaceutical composition comprising at least one compound according to claim 7 and a pharmaceutically-acceptable carrier or diluent.

### Claim 29 (depends on 20)

A pharmaceutical composition comprising at least one compound according to claim 20 and a pharmaceutically-acceptable carrier or diluent.

### Claim 30 (depends on 28)

A method of treating an inflammatory disorder comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 28.

### Claim 31 (depends on 30)

The method of claim 30 in which the inflammatory disorder is selected from asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, and arthritis including rhematoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis.
